CBS News
์ง๋ณด ์ฑํฅ
๊ธฐํ
What makes promising pancreatic cancer drug different from chemotherapy?
A new drug was shown in trials to keep pancreatic cancer patients alive for twice as long as chemotherapy alone. Dr. Jon LaPook has more.
๐บ๐ธ ๋ฏธ๊ตญ ยท "CHEMOTHERAPY" ยท ์ด 3๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
48.8
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 10,545๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 48.8(๊ท ํ)์ ๋๋ค. ๊ธ์ 1,048๊ฑด(9.9%)ยท์ค๋ฆฝ 7,545๊ฑด(71.6%)ยท๋ถ์ 1,952๊ฑด(18.5%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 22.4(๋ณด์ ๊ฒฝํฅ)์ ๋๋ค.
A new drug was shown in trials to keep pancreatic cancer patients alive for twice as long as chemotherapy alone. Dr. Jon LaPook has more.
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
When Pat Gentile began to grow out her hair after chemotherapy, she was nervous to go to work for the first time without a wig. An unexpected encounter with a convenience store stranger changed that.